Maximize Your Portfolio with Data Driven Insights:
- Leverage the power of TipRanks' Smart Score, a data-driven tool to help you uncover top performing stocks and make informed investment decisions.
- Monitor your stock picks and compare them to top Wall Street Analysts' recommendations with Your Smart Portfolio
Polarean Imaging ( (GB:POLX) ) has issued an update.
Polarean Imaging plc has signed its first international distribution agreement with Sumtage Enterprise Company Limited to expand the reach of its Xenon MRI platform into Taiwan. This partnership will help Polarean leverage Sumtage’s experience in the Taiwanese market to gain necessary regulatory approvals and address lung diseases such as lung cancer and COPD, potentially improving lung health outcomes with early-stage detection and treatment.
More about Polarean Imaging
Polarean Imaging plc is a medical imaging technology company that focuses on revolutionizing pulmonary medicine through the use of MRI for lung function visualization. The company is known for its development of the hyperpolarized Xenon MRI inhaled contrast agent, XENOVIEW®, which is FDA-approved in the United States. Polarean’s comprehensive platform includes a proprietary Xenon gas blend, a gas hyperpolarization system, and various software and accessories aimed at enhancing respiratory healthcare.
YTD Price Performance: 5.00%
Average Trading Volume: 12,427
Technical Sentiment Consensus Rating: Buy
Current Market Cap: $18.54M
See more insights into POLX stock on TipRanks’ Stock Analysis page.
